Cholesterol lowering drugs market is anticipated to grow at a significant CAGR during the forecast period . In general, cholesterol is considered to be fundamentally required by the body, however, more than 240 mg/dl is termed as high cholesterol. A total cholesterol of 200 mg/dl or lower is acceptable, and 200–240 mg/dl is considered borderline high. Such excessive level of cholesterol in the blood is known as hypercholesterolemia. High cholesterol may be a result of imbalanced diet, genetic diseases, obesity, or other diseases such as diabetes and an underactive thyroid. For instance, as per the International Diabetes Federation (IDF), the total adult population in the US suffering from diabetes was 31 million in 2019 while in Canada, it was 2.8 million. Moreover, there were around 189,000 mortalities due to diabetes in the US in 2019, which represents one of the highest numbers of mortalities all around the globe. Thus, the increased prevalence of diabetes as a result of high cholesterol is primarily driving the demand for cholesterol lowering drugs.
Apart from the common factors such as sedentary routines, increase in the consumption of saturated and trans-fat is also responsible for elevated levels of cholestrol all over the globe. The global cholesterol lowering drugs market is further likely to grow owing to the emergence of new drug classes, more effective therapies such as PCSK9 inhibitors, bempedoic acid, and the novel drugs in their pipeline phase. Although the major side effects of statins causing rhabdomyolysis as well as the easy accessibility to generic drugs of leading brands are projected to restrain the market growth during the forecast period.
To Request a Sample of our Report on Cholesterol Lowering Drugs Market: https://www.omrglobal.com/request-sample/cholesterol-lowering-drugs-market
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
Segment Covered-
- By Drug Class
- By Indication
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: AstraZeneca plc, Sanofi S.A., and Merck & Co., Inc., among others.
Cholesterol Lowering Drugs Market Report by Segment
By Drug Class
- Statins & Combination
- PCSK9 Inhibitor
- Bile Acid Sequestrants
- Fibrates
- Cholesterol Absorption Inhibitors
- Others
By Indication
- Hypercholesterolemia
- Coronary Artery Inhibitors
- Higher Triglycerides
A full Report of Cholesterol Lowering Drugs Market is Available @ https://www.omrglobal.com/industry-reports/cholesterol-lowering-drugs-market
Cholesterol Lowering Drugs Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
Comments (0)